Literature DB >> 2157062

The Epstein-Barr virus BRLF1 immediate-early gene product transactivates the human immunodeficiency virus type 1 long terminal repeat by a mechanism which is enhancer independent.

E B Quinlivan1, E Holley-Guthrie, E C Mar, M S Smith, S Kenney.   

Abstract

The Epstein-Barr virus (EBV) immediate-early gene product, BRLF1, transactivates the human immunodeficiency virus type 1 (HIV-1) long terminal repeat. BRLF1-induced transactivation of HIV-1 promoter constructs is accompanied by an increase in plasmid mRNA and is reporter gene independent. Previously, BRLF1 transactivation of EBV promoters has been mapped to regions which function as enhancer elements. Deletional analysis demonstrates that BRLF1 transactivation of the HIV-1 promoter does not require the HIV-1 enhancer. Thus, the EBV BRLF1 gene product may transactivate by at least two different mechanisms, one mechanism involving certain enhancer elements and another mechanism which is enhancer independent.

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2157062      PMCID： PMC249321          DOI： 10.1128/JVI.64.4.1817-1820.1990

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  34 in total

1.  The Epstein-Barr virus (EBV) BZLF1 immediate-early gene product differentially affects latent versus productive EBV promoters.

Authors:  S Kenney; J Kamine; E Holley-Guthrie; J C Lin; E C Mar; J Pagano
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

2.  The Epstein-Barr virus (EBV) DR enhancer contains two functionally different domains: domain A is constitutive and cell specific, domain B is transactivated by the EBV early protein R.

Authors:  A Chevallier-Greco; H Gruffat; E Manet; A Calender; A Sergeant
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

3.  The Epstein-Barr virus (EBV) early promoter DR contains a cis-acting element responsive to the EBV transactivator EB1 and an enhancer with constitutive and inducible activities.

Authors:  P Chavrier; H Gruffat; A Chevallier-Greco; M Buisson; A Sergeant
Journal:  J Virol       Date:  1989-02       Impact factor: 5.103

4.  The herpes simplex virus immediate-early protein, ICP4, is required to potentiate replication of human immunodeficiency virus in CD4+ lymphocytes.

Authors:  M A Albrecht; N A DeLuca; R A Byrn; P A Schaffer; S M Hammer
Journal:  J Virol       Date:  1989-05       Impact factor: 5.103

5.  Characterization of proteins encoded by the Epstein-Barr virus transactivator gene BMLF1.

Authors:  K M Wong; A J Levine
Journal:  Virology       Date:  1989-01       Impact factor: 3.616

6.  Activation of the human immunodeficiency virus long terminal repeat by herpes simplex virus type 1 is associated with induction of a nuclear factor that binds to the NF-kappa B/core enhancer sequence.

Authors:  J M Gimble; E Duh; J M Ostrove; H E Gendelman; E E Max; A B Rabson
Journal:  J Virol       Date:  1988-11       Impact factor: 5.103

7.  Alternative mechanisms for activation of human immunodeficiency virus enhancer in T cells.

Authors:  G J Nabel; S A Rice; D M Knipe; D Baltimore
Journal:  Science       Date:  1988-03-11       Impact factor: 47.728

8.  An Epstein-Barr virus immediate-early gene product trans-activates gene expression from the human immunodeficiency virus long terminal repeat.

Authors:  S Kenney; J Kamine; D Markovitz; R Fenrick; J Pagano
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

9.  Epstein-Barr virus genome-positive T lymphocytes in a boy with chronic active EBV infection associated with Kawasaki-like disease.

Authors:  H Kikuta; Y Taguchi; K Tomizawa; K Kojima; N Kawamura; A Ishizaka; Y Sakiyama; S Matsumoto; S Imai; T Kinoshita
Journal:  Nature       Date:  1988-06-02       Impact factor: 49.962

10.  Epstein-Barr virus BZLF1 trans-activator specifically binds to a consensus AP-1 site and is related to c-fos.

Authors:  P J Farrell; D T Rowe; C M Rooney; T Kouzarides
Journal:  EMBO J       Date:  1989-01       Impact factor: 11.598
View more
  11 in total

1.  Transcriptional control by the R-transactivator protein of alcelaphine herpesvirus-1.

Authors:  F M Frame; R G Dalziel
Journal:  Vet Res Commun       Date:  2007-11-20       Impact factor: 2.459

2.  The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes.

Authors:  T Ragoczy; L Heston; G Miller
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

3.  Activation of the Epstein-Barr virus DNA polymerase promoter by the BRLF1 immediate-early protein is mediated through USF and E2F.

Authors:  C Liu; N D Sista; J S Pagano
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

4.  Infection of primary CD4+ and CD8+ T lymphocytes by Epstein-Barr virus enhances human immunodeficiency virus expression.

Authors:  M Guan; R D Zhang; B Wu; E E Henderson
Journal:  J Virol       Date:  1996-10       Impact factor: 5.103

5.  Activation of the human immunodeficiency virus type 1 long terminal repeat by transforming mutants of human p53.

Authors:  M A Subler; D W Martin; S Deb
Journal:  J Virol       Date:  1994-01       Impact factor: 5.103

6.  Direct BRLF1 binding is required for cooperative BZLF1/BRLF1 activation of the Epstein-Barr virus early promoter, BMRF1.

Authors:  E B Quinlivan; E A Holley-Guthrie; M Norris; D Gutsch; S L Bachenheimer; S C Kenney
Journal:  Nucleic Acids Res       Date:  1993-07-11       Impact factor: 16.971

7.  The Epstein-Barr virus immediate-early gene product, BRLF1, interacts with the retinoblastoma protein during the viral lytic cycle.

Authors:  V L Zacny; J Wilson; J S Pagano
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

8.  The Epstein-Barr virus BZLF1 gene product activates the human immunodeficiency virus type 1 5' long terminal repeat.

Authors:  R Mallon; J Borkowski; R Albin; S Pepitoni; J Schwartz; E Kieff
Journal:  J Virol       Date:  1990-12       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 and hepatitis B virus transcription in peripheral blood lymphocytes from co-infected subjects.

Authors:  M Clementi; A Manzin; P Bagnarelli; S Menzo; P E Varaldo; G Carloni
Journal:  Arch Virol       Date:  1992       Impact factor: 2.574

10.  Reactivation of Epstein-Barr virus during early infection with human immunodeficiency virus.

Authors:  M A Rahman; L A Kingsley; R W Atchison; S Belle; M C Breinig; M Ho; C R Rinaldo
Journal:  J Clin Microbiol       Date:  1991-06       Impact factor: 5.948
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.